PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 31, 2026Signal Transduction and Targeted Therapy0 citationsOpen Access

Arterial inflammation after myocardial infarction: regulating the immune system

CKChristos P. KotanidisCACharalambos Antoniades

Key Result

Low-dose interleukin 2 significantly reduced arterial inflammation compared to placebo (mean TBRmax 2.04 vs 2.22) in patients with acute coronary syndromes and residual inflammation.

Key Points

  • The aim was to investigate the effects of low-dose interleukin 2 on arterial inflammation following myocardial infarction.
  • Selectively expanded regulatory T cells with low-dose interleukin 2.
  • Measured arterial inflammation using PET-CT imaging.
  • Focused on the ascending aorta and common carotid arteries.
  • Low-dose interleukin 2 significantly decreased arterial inflammation in aorta and carotid arteries.
  • The extent of inflammation reduction was visually confirmed through PET-CT imaging.

Structured PICO

Does low-dose IL-2 reduce arterial inflammation in patients with acute coronary syndromes and residual inflammation?

P
Population
63 patients presenting with unstable angina, NSTEMI, or STEMI (most treated with percutaneous coronary intervention) selected for residual inflammation defined by high-sensitivity C-reactive protein (hsCRP) > 2 mg/L.
I
Intervention
Low-dose interleukin 2 (IL-2) 1.5 × 10^6 IU subcutaneous injection once daily for 5 days (induction phase), followed by once-weekly injections for 7 weeks (maintenance phase).
C
Comparator
Placebo (subcutaneously administered 5% glucose).
O
Outcome
Arterial inflammation measured on [18F]FDG PET-CT scan of the ascending aorta and carotids at the end of an 8-week treatment period.surrogate

Low-dose IL-2 selectively expands regulatory T cells and reduces arterial inflammation in patients with acute coronary syndromes, introducing a novel paradigm of augmenting endogenous adaptive immunity.

Main Result

Absolute Event Rate: 2.04% vs 2.22%

Limitations

  • Small cohort size
  • High baseline inflammatory burden
  • Sex imbalance (predominantly male participants)
  • Limited ethnic diversity
  • Exclusion of patients with insulin-treated diabetes
  • Imaging focused on the aorta and carotids rather than the coronary arteries
  • Small sample size and relatively short follow-up for clinical events
  • Sex imbalance (predominantly male participants) and limited ethnic diversity
  • Low prevalence of diabetes mellitus (insulin-treated diabetes excluded)

Abstract

In a recent study published in Nature Medicine by Sriranjan-Rothwell et al. 1 selectively expanding regulatory T cells ( T reg ) with low-dose interleukin 2 (IL-2) led to a decrease in arterial inflammation measured on PET-CT imaging of the ascending aorta and common carotid arteries.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Kotanidis et al. (2026) conducted an editorial in Acute coronary syndromes (unstable angina, NSTEMI, or STEMI) (n=63). Low-dose interleukin 2 (IL-2) vs. Placebo (5% glucose subcutaneous injection) was evaluated on Arterial inflammation (mean TBRmax on PET-CT of ascending aorta and carotids). Low-dose interleukin 2 significantly reduced arterial inflammation compared to placebo (mean TBRmax 2.04 vs 2.22) in patients with acute coronary syndromes and residual inflammation.

synapsesocial.com/papers/6a025c76edf6f4813859466dhttps://doi.org/10.1038/s41392-026-02628-1
Ask AI
Helpful
Bookmark
Share
View Full Paper